KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Pacific Biosciences Of California (PACB) Gross Margin (2016 - 2025)

Pacific Biosciences Of California has reported Gross Margin over the past 16 years, most recently at 37.11% for Q4 2025.

  • Quarterly results put Gross Margin at 37.11% for Q4 2025, up 1146.0% from a year ago — trailing twelve months through Dec 2025 was 28.61% (up 440.0% YoY), and the annual figure for FY2025 was 28.61%, up 440.0%.
  • Gross Margin for Q4 2025 was 37.11% at Pacific Biosciences Of California, down from 41.36% in the prior quarter.
  • Over the last five years, Gross Margin for PACB hit a ceiling of 46.55% in Q4 2021 and a floor of 3.69% in Q1 2025.
  • Median Gross Margin over the past 5 years was 32.68% (2023), compared with a mean of 31.55%.
  • Peak annual rise in Gross Margin hit 2044bps in 2025, while the deepest fall reached -3276bps in 2025.
  • Pacific Biosciences Of California's Gross Margin stood at 46.55% in 2021, then tumbled by -60bps to 18.79% in 2022, then decreased by -13bps to 16.4% in 2023, then surged by 56bps to 25.64% in 2024, then skyrocketed by 45bps to 37.11% in 2025.
  • The last three reported values for Gross Margin were 37.11% (Q4 2025), 41.36% (Q3 2025), and 36.93% (Q2 2025) per Business Quant data.